Two Sigma Investments LP Sells 29,496 Shares of Generation Bio Co. (NASDAQ:GBIO)

Two Sigma Investments LP trimmed its position in shares of Generation Bio Co. (NASDAQ:GBIO) by 19.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 120,403 shares of the company’s stock after selling 29,496 shares during the period. Two Sigma Investments LP owned about 0.18% of Generation Bio worth $128,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in shares of Generation Bio during the fourth quarter valued at approximately $25,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Generation Bio by 13.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 311,535 shares of the company’s stock worth $330,000 after acquiring an additional 38,090 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Generation Bio during the 4th quarter worth approximately $77,000. Millennium Management LLC purchased a new position in Generation Bio during the 4th quarter valued at $97,000. Finally, JPMorgan Chase & Co. grew its position in Generation Bio by 74.9% in the 4th quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock valued at $316,000 after acquiring an additional 127,513 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Stock Down 1.8%

GBIO opened at $0.38 on Friday. The stock’s fifty day moving average is $0.39 and its two-hundred day moving average is $0.68. The company has a market capitalization of $25.67 million, a P/E ratio of -0.17 and a beta of 2.66. Generation Bio Co. has a 52 week low of $0.32 and a 52 week high of $3.65.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. The firm had revenue of $8.72 million for the quarter, compared to analyst estimates of $1.70 million. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%. Equities analysts anticipate that Generation Bio Co. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

GBIO has been the subject of several research analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $9.00 target price on shares of Generation Bio in a research report on Monday, March 17th. Wedbush reiterated an “outperform” rating and set a $5.00 price objective on shares of Generation Bio in a report on Friday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Generation Bio in a research report on Thursday, May 8th.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.